The company completed the acquisitions of Signify Health and Oak Street Health in 2023, enhancing its care delivery strategy by advancing primary care, home-based care and provider enablement capabilities.

The company announced the launch of Cordavis, a wholly owned subsidiary that will work directly with pharmaceutical manufacturers to commercialize and/or co-produce high quality biosimilar products.

The company expanded its participation in the Public Exchanges to 17 states in 2024, up from 12 states in 2023, indicating a focus on individual consumer markets.

The company realigned its segments to reflect how the Chief Operating Decision Maker reviews information and manages the business, creating a new Health Services segment and Pharmacy & Consumer Wellness segment.

The company completed a strategic review of its retail business and announced plans to reduce store density in certain locations through the closure of approximately 900 retail stores between 2022 and 2024.

The company has continued to invest in information systems to enable it to deliver exceptional customer service, enhance safety and quality, and expand patient care services while lowering operating costs.

The company's operations are subject to comprehensive federal, state and local laws and regulations, and changes to these could adversely affect the company's businesses.

The company faces intense competition in the health care benefits and health services industries, which could impact its ability to obtain new customers or retain existing ones.

The company and its vendors have experienced and continue to experience information security incidents, which could disrupt operations and expose sensitive data.

The company faces strong competition from a large number of for-profit and not-for-profit competitors in the health care benefits industry.

The health services segment faces competition from large national PBM companies and PBMs owned by large national health plans.

The retail pharmacy business faces competition from other drugstore chains, supermarkets, discount retailers, online retailers and mail order pharmacies.

The company emphasizes the ability to identify and apply effective cost management programs utilizing clinical strategies, including the development and utilization of preferred formularies.

The company is investing in information systems to enable it to deliver exceptional customer service, enhance safety and quality, and expand patient care services while lowering operating costs.

The company completed a strategic review of its retail business and announced its plans to reduce store density in certain locations through the closure of approximately 900 retail stores between 2022 and 2024.

The company is making concerted investments in enterprise data platforms, cloud capabilities, and digital products to offer innovative solutions and a seamless experience to its members.

The company is making investments in emerging technology capabilities such as voice, artificial intelligence and robotics to further automate, reduce cost and improve the experience for all of its constituents.

The company has established critical tools which enable patients to schedule appointments through MinuteClinic.com and access digital results for tests and records.

The company has authorized share repurchase programs, which allow for repurchases through open market transactions, privately negotiated transactions, accelerated share repurchases and/or other derivative transactions.

In December 2023, the Board authorized an increase of approximately 10% in the quarterly cash dividend to $0.665 per share effective in 2024.

The company used cash on hand and debt to fund the acquisitions of Signify Health and Oak Street Health.

The company has outlined its Healthy 2030 ESG strategy, which is constructed through a four-pillar framework: Healthy People, Healthy Business, Healthy Community and Healthy Planet.

The company has a Diversity Management Leadership Council and supports Colleague Resource Groups to promote diversity, equity, inclusion and belonging.

The company is committed to achieving net-zero emissions from its direct operations by 2048 and across its value chain by 2050.

Adverse economic conditions in the U.S. and abroad, including inflation and high interest rates, can materially impact the company's businesses, operating results, cash flows and financial condition.

The company's Medicare Advantage and PDP products are heavily regulated by CMS, and changes to these regulations could impact the company's business.

The company is seeking to grow its Medicaid business, which increases its exposure to changes in government policy with respect to and/or regulation of the various Medicaid programs.